ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancer

{ Posted on Feb 07 2010 by admin }
Categories : Health News

ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene. ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase…


Related posts:

  1. ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancer ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase...
  2. ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancer ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase...
  3. ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancer ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase...
  4. Poniard Pharmaceuticals Announces Phase 2 Trial Of Picoplatin In Metastatic Colorectal Cancer Meets Primary Endpoint And Study Objectives Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on...
  5. Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer The Committee for Medicinal Products for Human Use (CHMP), the...
This entry was posted on Sunday, February 7th, 2010 at 1:00 am and is filed under Health News. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Post a Comment